trial · primary record
Mobocertinib
Non-Small Cell Lung Cancer
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 53 |
| Primary completion | 2026-10-28 |
| Primary endpoint | Phase 1 Part: Recommended Phase 2 Dose (RP2D) of Orally Administered Mobocertinib |
| Registry ID | NCT03807778 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:13.340Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03807778
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.